Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability.

The poorly soluble drug buparvaquone is used in experimental clinics against the gastrointestinal persisting parasite Cryptosporidium parvum. It was produced as nanosuspension by high pressure homogenisation. Main advantages of nanosuspensions (amongst others) are their increase of saturation solubility and dissolution velocity, improving the bioavailability of drugs. The buparvaquone nanosuspension had a bulk population of about 600 nm (analysed by photon correlation spectroscopy (PCS)). The additional analysis performed with laser diffraction showed that only a very small content of microparticles occurred, which is, for the special features of nanosuspensions, negligible because they were still below 3 microm. Another feature of nanosuspensions is the adhesion properties to surfaces, e.g. mucosa. To further increase the adhesion time of the buparvaquone nanosuspension to C. parvum, the nanosuspension was formulated with hydrogels made from mucoadhesive polymers, e.g. different types of Carbopol and chitosan. Only a small increase of the particle size of the bulk population occurred directly after the incorporation of buparvaquone nanosuspension into the hydrogels. The nanosuspension/hydrogel systems were physically long-term stable over a period of 6 months as indicated by the unchanged particle sizes.

[1]  G. Liversidge,et al.  Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs , 1995 .

[2]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[3]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[4]  Mitra Mosharraf,et al.  The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs , 1995 .

[5]  S. Mortazavi,et al.  An investigation of some factors influencing the in vitro assessment of mucoadhesion , 1995 .

[6]  H. Ch'ng,et al.  Evaluation of possible mechanism(s) of bioadhesion , 1998 .

[7]  R. Laing.  Nosocomial infections in patients with HIV disease. , 1999, The Journal of hospital infection.

[8]  H. Junginger,et al.  Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro , 1997 .

[9]  S. Jahnke.  The theory of high-pressure homogenization , 2001 .

[10]  G. Smistad,et al.  Bioadhesion of hydrated chitosans: An in vitro and in vivo study , 1996 .

[11]  O. Kayser,et al.  A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications. , 2001, International journal of pharmaceutics.

[12]  Donald L. Wise,et al.  Nanosuspensions: A Formulation Approach for Poorly Soluble and Poorly Bioavailable Drugs , 2000 .

[13]  Dominique Duchêne,et al.  Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract , 1997 .